REVIEW ARTICLE

Development of cannabidiol as a treatment for severe childhood epilepsies

Claire M. Williams1 | Gary J. Stephens2

1School of Psychology and Clinical Language Science, University of Reading, Reading, Berkshire, UK
2School of Pharmacy, University of Reading, Reading, Berkshire, UK

Correspondence
Gary J. Stephens, School of Pharmacy, University of Reading, Whiteknights, Reading, Berkshire RG6 6UB, UK.
Email: g.j.stephens@reading.ac.uk

Funding information
GW Pharmaceuticals

In recent years, there has been a growing appreciation by regulatory authorities that cannabis-based medicines can play a useful role in disease therapy. Although often conflagrated by proponents of recreational use, the legislative rescheduling of cannabis-derived compounds, such as cannabidiol (CBD), has been associated with the steady increase in the pursuit of use of medicinal cannabis. One key driver in this interest has been the scientific demonstration of efficacy and safety of CBD in randomised, placebo-controlled clinical trials in children and young adults with difficult-to-treat epilepsies, which has encouraged increasing numbers of human trials of CBD for other indications and in other populations. The introduction of CBD as the medicine Epidiolex in the United States (in 2018) and as Epidyolex in the European Union (in 2019) as the first cannabis-derived therapeutic for the treatment of seizures was underpinned by preclinical research performed at the University of Reading. This work was awarded the British Pharmacological Society Sir James Black Award for Contributions to Drug Discovery 2019 and is discussed in the following review article.

KEYWORDS

cannabidiol, Dravet syndrome, epilepsy

1 INITIAL INTEREST IN CANNABIS COMPONENTS FOR TREATMENT OF EPILEPSIES

General interest in the potential therapeutic utility of non-tetrahydrocannabinol (THC) cannabinoids was pioneered by researchers such as Raphael Mechoulam at the Hebrew University of Jerusalem in Israel and Roger Pertwee, initially at Oxford University and then at Aberdeen University. Prior to joining the University of Reading, Ben Whalley, working with Andrew Constanti and Elizabeth Williamson at the London School of Pharmacy, had shown that standardised cannabis extracts lacking THC could inhibit muscarinic receptor agonist-induced epileptiform-like activity in ex vivo rat piriform cortical brain slices (Wilkinson et al., 2003). In parallel, Gary Stephens had an interest in the coupling of G protein-coupled receptors (GPCRs), such as cannabinoid CB1 receptors, to downstream signalling pathways including voltage-gated calcium channels (Stephens, Cantl, Page, & Dolphin, 1998; Stephens & Mochida, 2005; reviewed in Stephens, 2009). Claire Williams had complementary expertise in animal models of disease and, working with Tim Kirkham at Reading, had reported extensively on the effects of plant-derived

Abbreviations: AED, anti-epileptic drug; CBD, cannabidiol; CBDV, cannabidivarin; CBG, cannabigerol; CBPM, cannabis-based products for medicinal use; DS, Dravet syndrome; FDA, Food and Drug Administration; GPCR, G protein-coupled receptor; GPR18, GPCR 18; GPR55, GPCR 55; LGS, Lennox–Gastaut syndrome; MES, maximal electroshock seizure; PTZ, pentylentetrazole; RISE-SRS, reduced intensity status epilepticus-spontaneous recurrent seizures; THC, tetrahydrocannabinol; THCV, tetrahydrocannabivarin; TRPA1, transient receptor potential ankyrin 1; TRPV1, transient receptor potential vanilloid 1; TRPV2, transient receptor potential vanilloid 2; TSC, Tuberous Sclerosis Complex; VDAC1, voltage-dependent anion-selective channel protein 1; VGSC, voltage-gated sodium channel.
phytocannabinoids, endocannabinoids, and exogenous cannabinoids in
appetitive behavioural models. This work had demonstrated the role
of CB₁ receptors in hyperphagia and highlighted the potential to
target such receptors in obesity disorders (Williams & Kirkham, 1999;
Williams, Rogers, & Kirkham, 1998; reviewed in Kirkham &
Williams, 2004).

The common research interest of the team at Reading centred
around epilepsy, a range of syndromes characterised by hyper-
excitable neural networks in the brain, which clinically manifest as
seizures and are associated with a clear unmet clinical need. World-
wide, there are around 65 M people with epilepsy, making it the
most prevalent global neurological condition; however, around one
third of patients with epilepsy do not respond to current anti-
epileptic drugs (AEDs) and therefore live with uncontrolled seizures
(Jannmohamed, Brodie, & Kwan, 2019). Despite anecdotal reports of
cannabis having therapeutic benefit in epilepsy, there had been little
rigorous scientific research between 1970 and 2010 to support any
clinical use, in particular with regard to preclinical efficacy, or safety
of cannabinoids, endocannabinoids, and exogenous cannabinoids
in appetite and toxicity data. Our focus, cannabinol (CBD), was isolated in
1963 (Mechoulam & Shvo, 1963) and first investigated functionally
in the early 1970s (Paton & Pertwee, 1972). Amongst a few small-
scale case studies, of particular interest was a study in Brazil
suggested that plant-derived CBD had potential utility in seizures
(Cunha et al., 1980). By contrast, some reports had implicated THC as
a pro-convulsant agent (as discussed in Rosenberg, Tsien,
Whalley, & Devinsky, 2015). These findings were further set against
the desire to find agents that did not promote the euphoria associ-
ated with recreational THC use.

The interest in use of non-psychoactive cannabinoids was
supported by the introduction of Sativex (nabiximols, a 50:50 mixture
of the two principal components of Cannabis sativa, THC and CBD) to
relieve spasticity and pain associated with multiple sclerosis, rep-
 resenting the first cannabis-based medicine to be licensed in the
United Kingdom. Thus, Stephens, Whalley, and Williams began collab-
orating with the intention of testing isolated cannabinoid extracts in
seizure and epilepsy models. The makers of Sativex, GW Pharmaceuti-
cals, initially partnering with Otsuka Pharmaceuticals, Japan, provided
funding in 2007 to conduct preclinical research to assess the ther-
apeutic potential of isolated phytocannabinoids in rodent models of
chemically induced seizures and associated in vitro studies to investi-
gate modes and mechanisms of action. Individual phytocannabinoids,
including CBD, were investigated as botanical drug substances.

Initial work using the Mg²⁺-free and the 4-aminopyridine models
of epileptiform activity in ex vivo rat hippocampal brain slices dem-
 onstrated clear CBD effects on local field potential burst amplitude, dura-
tion, and frequency in different cornus ammonis and dentate gyrus
regions (Jones et al., 2010). Complementary work investigated the
effects of CBD, applied via the intraperitoneal route, in a range of rat
models of acute seizure induced by chemicals including
pentyleneterazol (PTZ) (to model generalised seizures) (Jones et al., 2010), pilocarpine (temporal lobe seizures), and penicillin (partial
seizures) (Jones et al., 2012). Our initial in vivo work identified CBD as
a major phytocannabinoid with the greatest anticonvulsant potential
across all of the acute seizure models tested (Figure 1). It was simi-
larly shown that intraperitoneal CBD was anticonvulsant in rat and
mouse maximal electroshock seizure (MES) models, and in 6-Hz
psychomotor and corneal kindling models, and that intravenous
CBD was also effective in reduced seizure severity in the pilocar-
pine model (Patra et al., 2019; Figure 1). The latter study also
showed that chronic administration of CBD oral solutions attenu-
ated seizure burden and motor co-morbidities in the rat reduced
intensity status epilepticus-spontaneous recurrent seizures (RIE-
SRS) model of temporal lobe epilepsy (TLE) (Patra et al., 2019), the
RIE-SRS model being developed between researchers at University
of Reading and Gavin Woodhall’s group at Aston University
(Modebadze et al., 2016). From a pharmacological viewpoint, CBD
was shown to possess only low, non-relevant binding affinity at
CB₁ receptors (Jones et al., 2010); this work was in line with stud-
ies by other groups (as reviewed by Pertwee, 2008). These data
also supported earlier work in the MES model in mice by Lisa Wall-
ace and co-workers, who demonstrated that CBD had an anticon-
vulsant action, independent of effects on CB₁ receptors (Wallace,
Wiley, Martin, & Delorenzo, 2001). Following the investigation of
CBD in human genetic paediatric epilepsies (described more fully
below), we extended our studies to the effects of CBD in
corresponding mouse models. In particular, we investigated models
of Dravet syndrome (DS), a genetic disease due to a voltage-gated
sodium channel (VGSC) Scn1a gene mutation. It was shown that
chronic CBD (100 mg·kg⁻¹ injected subcutaneously twice daily)
treatment was able to increase survival in Scn1a⁻/⁻ mice and pre-
vent premature mortality and improve associated co-morbidities in

![FIGURE 1](image)

**FIGURE 1** CBD reduces seizure severity in different rat models of chemically induced acute seizure. Intraperitoneal CBD (100 mg·kg⁻¹) caused a significant reduction in seizure severity induced by pentylene tetrazolate (80 mg·kg⁻¹, n = 15; Jones et al., 2010), penicillin 525 IU intracerebroventricular infusion (n = 17–18; Jones et al., 2012), or pilocarpine (380 mg·kg⁻¹, n = 15; Jones et al., 2010). Intravenous CBD (10 mg·kg⁻¹) caused a significant reduction in seizure severity induced by pilocarpine (380 mg·kg⁻¹ i.v., n = 12–15; Patra et al., 2019). *P < 0.05, nonparametric binomial test.
Scn1a°/− mice (Patra et al., 2020). Such preclinical work provided a strong association with the clinical data that had emerged following our initial work.

We have also investigated the effects of other phytocannabinoids. These compounds included the THC homologue tetrahydrocannabinol (THCV), cannabigerol (CBG), and the CBD homologue cannabidiol (CBDV). We initially showed that THCV had actions analogous to CB1 receptor antagonists on inhibitory neurotransmission at interneuron-Purkinje cell synapses (Ma, Weston, Whalley, & Stephens, 2008). THCV was also shown to act as a CB1 receptor antagonist in ligand binding and GTPγS binding assays (Dennis, Whalley, & Stephens, 2008; Hill et al., 2010). Interestingly, THCV reduced epileptiform activity induced by Mg2+-free media in adult rat piriform cortical brain slices and demonstrated anticonvulsant effects against PTZ-induced generalised seizures in adult rats (Hill et al., 2010). The potential clinical utility of CB1 receptor antagonists was however challenged by the high-profile withdrawal of the prototypic agent rimonabant. CBG was also shown to lack anticonvulsant effects in the PTZ model of generalised seizures (Hill et al., 2014). More prominently, we also demonstrated that CBDV possessed useful anticonvulsant effects in in vitro and in vivo seizure models (Amada, Yamasaki, Williams, & Whalley, 2013; Hill, Williams, Whalley, & Stephens, 2012). The former study further detailed the suppressive effects of CBDV on expression of specific epilepsy-related genes. We further demonstrated that the anticonvulsant effects of CBDV-rich cannabis extracts occurred independently of actions at CB1 receptors (Hill et al., 2013). There are ongoing investigations into the potential clinical utility of CBDV in epilepsy; however, overall preclinical data in vivo and seizure models generated at the University of Reading strongly suggested CBD as a prominent cannabinoid which had clear potential to address the unmet clinical need associated with different forms of epilepsy.

2 | THE HUMAN EXPERIENCE

In parallel with efforts within the scientific research community, families of children with difficult-to-treat childhood epilepsies were beginning to connect with cannabis growers who were developing previously ‘forgotten’ high-CBD cannabis strains. The realisation that such strains may possess anti-seizure effects began to emerge via social and mainstream media. A notable example was the story of Charlotte Figi, which was captured in a memorable 2013 CNN documentary. At that time, Charlotte was a 5-year-old American girl who suffered dozens of seizures a day due to intractable DS, a disease associated with average life expectancy of just 8 years. Local producers of cannabis oil in Colorado developed a specialised high CBD/low THC product, later dubbed "Charlotte's Web," which was able to cause a remarkable reduction in Charlotte's seizure rate (Maa & Figi, 2014). Against a backdrop of Charlotte being a twin to a healthy sister, together with her father being in the US military, the human-interest documentary helped propel potential use of ‘medical marijuana’ into the public’s consciousness. Other growers began to develop high CBD/low THC strains, and several families began to seek access to such strains, some via knowledge of the publications from University of Reading. In particular, the mother of Sam Vogelstein (a child with intractable childhood epilepsy who became Epidiolex patient #1) contacted GW Pharmaceuticals, citing the work of Jones et al. (2010), to request access to CBD. The treatment reportedly had significant efficacy—after 3 days of treatment, Sam was down from dozens of seizures per day to around one seizure per day. This led to the family being permitted by the Food and Drug Administration (FDA) to use CBD under a compassionate use program in California; the success of this program led to the pursuit of wider trials across more epilepsy centres. Thus, one of the foremost US epilepsy clinicians, Orrin Devinsky, Professor of Neurology at NYU Langone School of Medicine, oversaw moves towards the first randomised, controlled human clinical trials of CBD in patients with DS and another devastating paediatric epilepsy, Lennox–Gastaut syndrome (LGS). DS and LGS represent two of the most difficult to treat genetic childhood epilepsy syndromes; as patients with these syndromes have severely reduced lifespans and are commonly resistant to traditional AEDs, they represented a significant unmet need for new therapeutic options. These trials were further facilitated by the FDA decision in 2013 to grant CBD an Orphan Drug designation (i.e., special status to a drug with clear potential treat a rare disease, as defined in the United States as a condition that affects fewer than 200,000 people). Although classified as ‘rare’ orphan diseases, figures from National Organization for Rare Diseases can be used to estimate that there are around 45,000–70,000 patients with DS and LGS in the United States. Such people with epilepsy present with multiple seizure types, commonly resistant to traditional AEDs, as well as developmental delay and numerous co-morbidities.

From 2014, open-label trials in patients with treatment-resistant epilepsy, including DS and LGS, were initiated. Such trials first reported an encouraging 36.5% median reduction in monthly motor seizures (Devinsky et al., 2016). Following successful Phase 2 trials (Devinsky et al., 2017; Devinsky, Patel, Thiele, & GWPCARE1 Part A Study Group, 2018), the first pivotal positive Phase 3 study results for CBD in the treatment of DS and LGS were announced. Each of these clinical studies recruited patients typically with a history of using at least two previous AEDs and displaying at least two uncontrolled seizures weekly during a 4-week pretreatment baseline. Across the studies, treatment groups displayed a significant ~20 percentage point decrease in seizures compared to placebo. Based on these positive human trials, the FDA approved Epidiolex as the first prescription plant extract cannabinoid medicine in the United States and as the first in a new class of anti-epileptic medications for the treatment of pharmacoresistant seizures in children and young adults with DS and LGS. Overall, the GWPCARE1 and GWPCARE2 trials demonstrated that an oral suspension of CBD at 10 or 20 mg·kg−1·day−1 two times a day had an acceptable safety profile and that individuals with treatment-resistant DS achieved a sustained, clinically meaningful reduction in monthly convulsive seizures compared with a placebo (Devinsky et al., 2017; Devinsky, Patel, Thiele, et al., 2018; Miller et al., 2020). Similarly, Phase 3 trials
for oral CBD in LGS (GWPCARE3 and GWPCARE 4) were also positive (Devinsky, Patel, Cross, et al., 2018; Thiele et al., 2018). Thus, four major trials were carried out, recruiting a total of 550 (DS, 154; LGS, 396) patients who had previously been unable to control their seizures despite AED polytherapy (see Morano et al., 2020). An open-label extension trial, GWPCARE5, with 630 subjects (DS, 264; LGS, 366) further supported oral CBD safety and persistence efficacy in DS and LGS patients (Devinsky et al., 2019; Thiele, Bebin, et al., 2019). Prior to Epidiolex being available for prescription, it has been estimated that over 2,000 patients had already been treated through GW’s compassionate use program and open-label extension. Epidiolex became available for prescription in the United States in November 2018. The Drug Enforcement Agency reclassified CBD (containing no more than 0.1% [w/w] residual THC) to Schedule V, indicating proven medical use and low potential for abuse. Similar European Medicine Authority approval for CBD followed in 2019, under the brand name Epidyolex. In the United Kingdom, the medicine became fully available on the NHS in January 2020. Drug scheduling of cannabis in the United Kingdom has been under regular review, and in November 2018, “cannabis-based products for medicinal use (CBPMs)” were reclassified from Schedule 1 controlled drugs (compounds of no medical value) into Schedule 2 of the Misuse of Drugs Regulations 2001. Most recently, Epidyolex was reclassified as a Schedule 5 drug in the United Kingdom.

During approval, FDA Commissioner Scott Gottlieb stated in a press release: “This approval serves as a reminder that advancing sound development programs that properly evaluate active ingredients contained in marijuana can lead to important medical therapies. And, the FDA is committed to this kind of careful scientific research and drug development.”

### 3 CBD MECHANISM OF ACTION

A definitive pharmacological target for CBD in epilepsy (and elsewhere) remains elusive, with various reports of pharmacologically relevant affinity at several molecular targets (Gray & Whalley, 2020; Senn, Cannazza, & Biagini, 2020). The best recognised targets include transient receptor potential vanilloid channels and **GPCR 18** (GPR18) and **GPR55** receptors (Alexander et al., 2019). Work at the University of Reading has contributed to descriptions of CBD activation, and subsequent desensitisation, of **transient receptor potential vanilloid 1** (TRPV1), **TRPV2**, and **transient receptor potential ankyrin 1** (TRPA1) (Iannotti et al., 2014). We have also shown that CBD blocks the activation of GPR55 receptors by the endogenous lipid agonist lysophosphatidylinositol in ex vivo brain slices taken from rats displaying spontaneous epileptiform activity (Rosenberg et al., 2018).

Pharmacological blockage/antagonism and/or transgenic technology is good evidence to define mechanism of action. One recent study demonstrates that CBD’s anticonvulsant properties were attenuated in TRPV1 knockout mice (Gray, Stott, Jones, Di Marzo, & Whalley, 2020). CBD also acts as allosteric modulator of 5HT1A; however, one specific study has ruled out 5HT1A as a CBD target in seizure control (Pelz, Schoolcraft, Larson, Spring, & Lopez, 2017). CBD was also shown to act as a blocker of VGSCs (Hill et al., 2014), which represents a potential mode of anticonvulsive action in epilepsy. However, another phytocannabinoid, CBG, was shown to share blockade of VGSCs but, unlike CBD, had no clear effect on PTZ-induced seizures in rats (Hill et al., 2014). CBD has also been shown to retain anti-seizure effects and improve social deficits and survival in a mouse model of DS (Kaplan, Stella, Catterall, & Westenbroek, 2017; Patra et al., 2020), itself a syndrome associated with a loss-of-function mutation to NaV1.1 VGSCs. Moreover, nanomolar CBD was effective in regulating neuronal excitability without effects on VGSCs in a human-induced pluripotent stem cell-based model of DS (Sun & Dolmetsch, 2018). Such data suggest that VGSCs were not the primary CBD target in epilepsy; these findings are significant as current AEDs which act as VGSC blockers are known to exacerbate DS.

As described above, CBD has only very low affinity at CB1 receptors; correspondingly, CBD lacks any appreciably coupling to G protein turnover (Jones et al., 2010). There are however reports that CBD can act as a negative allosteric modulator at CB1 receptors (Laprairie, Bagher, Kelly, & Denovan-Wright, 2015; Strakier, Dvorakova, Zimmowitch, & Mackie, 2018) and also as a partial agonist at CB2 receptors (Tham et al., 2019). Of further mechanistic interest is our recent study which was consistent with CBD ameliorating the pro-convulsant effect of long-term THC treatment in rats (Whalley et al., 2018). In this study, we also described a potential mechanism whereby CBD reduced THC-mediated CB1 receptor activation in a species-specific way (Figure 2); such CBD actions may reflect a functional reduction in seizures, for example, via negative allosteric modulation of CB2 receptors.

Several other potential molecular targets of CBD, including classical receptors, ion channels, transporters, and enzymes, have been proposed (reviewed by us in Hill et al., 2012; Ibeas Bih et al., 2015; Turner, Williams, Iversen, & Whalley, 2017). Most prominent amongst these are alternative receptor targets including 5HT1A, adenosine receptor subtypes, and PPARγ nuclear receptors; additional ion channel targets including CaV3 voltage-gated calcium channels and mitochondrial voltage-dependent anion-selective channel protein 1 (VDAC1); adenosine transporters; and, potentially, enzymes involved in the endocannabinoid system, such as fatty acid amide hydrolase. One common CBD effect may be the modulation of downstream levels of calcium as a second messenger (see Ibeas Bih et al., 2015). In this regard, CBD has been proposed to regulate mitochondrial control (potentially via VDAC1) of intracellular calcium levels in hippocampal neurons and to restore homeostasis in pathological situations (Ryan, Drysdale, Lafourcade, Pertwee, & Platt, 2009); such function may contribute to CBD effects in epilepsy. More recently, we and co-workers have shown that CBD can act on a glycine cleavage system component to inhibit synthesis of the essential amino acid methionine, including in heterozygous Scn1a+/− mice in the DS model (Perry et al., 2020). This work introduces one-carbon signalling as a further potential target for CBD action.

A potential confounder in some studies is the use of high (~>10 μM) CBD concentrations. As discussed by us previously, the
The lipophilic nature of CBD means that results based on higher micromolar concentrations of CBD are likely influenced by insertion of CBD into the plasma membrane (Ibeas Bih et al., 2015). In practice, the poor bioavailability of CBD in vivo (see below) may limit these effects. However, the general lipophilic profile of cannabinoids, including CBD, also means that they have potential to accumulate in fatty tissue and be released over time. In general, more credence is typically placed on CBD effects that occur at low/sub-micromolar concentrations. Overall, CBD may exhibit a relevant “polypharmacology” profile; there are also consistent reports of anti-oxidant and anti-inflammatory properties of CBD which have potential to contribute to anti-epileptic (and other) effects.

Finally here, the lack of a well-defined molecular target can lead to speculation about the potential role of metabolites. In humans, CBD is metabolised mainly into 7-OH-CBD and the major 7-COOH-CBD metabolite. However, work on effects of CBD metabolites is, as yet, still in its infancy.

**FIGURE 2** CBD affects THC-stimulated 35S-GTPγS turnover in cerebellar tissue in a species-specific manner. CBD (applied at a THC:CBD 1.08:1 ratio) attenuated THC-stimulated G protein turnover in rat and chicken, but not human, tissue. Note that in human tissue, THC-stimulated G protein turnover was of generally lower magnitude. *P < 0.05, ANOVA followed by a Tukey’s post hoc test on raw data from three separate experiments in triplicate, preparations from multiple brains (data derived from Whalley et al., 2018)

4 | CLINICAL/FUTURE PERSPECTIVES

Over the last few years, there has been an explosion in interest in the use of CBD-containing foods and supplements, supported by widespread availability of numerous different CBD preparations on the High Street and of further unregulated access via the internet. There have been recent warnings about levels of such consumption from the UK Food Standards Agency and efforts to curtail many unsubstantiated claims of therapeutic benefit. The latter will, of course, require controlled human trials which investigate appropriate formulations of standardised product, delivered at an efficacious dose. The original case of Charlotte Figi described above has several recent parallels in the United Kingdom. The publicity around cases of uncontrolled childhood epilepsies, such as those of Billy Caldwell and Alfie Dingley, were key in the reclassification and increased availability of CBPMs, including those with a CBD component. These moves were no doubt also fuelled by the approval of Epidiolex as a scientifically tested medicine.

From a clinical viewpoint, there are challenges to effective delivery of CBD. Animal studies suggest that CBD oral bioavailability is low (<20%) (Mechoulam, Parker, & Gallily, 2002), with CBD being subject to extensive first-pass metabolism (Huestis, 2007); however, wide-ranging human data for CBD bioavailability are currently lacking (Millar et al., 2019). CBD is also associated with low water solubility and variability in pharmacokinetic profiles (Millar, Maguire, Yates, & O'Sullivan, 2020). Therefore, further work is needed to establish therapeutic dosing and most effective route of administration. Clinically, Epidiolex is given as an oral solution; in addition, the CBD-containing medicine Sativex is administered sublingually to avoid first-pass metabolism. CBD bioavailability may be improved by intranasal delivery (e.g., of vaporised drug) or even by transdermal delivery (Paudel, Hammell, Agu, Valivet, & Stinchcomb, 2010). However, of interest for anticonvulsant effects is that CNS levels of CBD were found to be higher via the oral, compared to the inhaled, route; moreover, such exposure correlated with increased behavioural effects (Hložek et al., 2017).

There is a well-described “entourage effect,” originally posited for the endocannabinoid system by Ben-Shabat et al. (1998), whereby cannabinoid effects are synergically increased by associated components. Such effects have also been ascribed to CBD and to Epidiolex, which represents a 98% CBD plant extract; however, future controlled human trials will be required to more fully define this effect. Some evidence in support of CBD synergism comes from a recent meta-analysis of observational clinical studies that concluded patients required ~4-fold less CBD dose in enriched plant extracts versus purified drug and that adverse effects were also reduced in extracts (Pamplona, da Silva, & Coan, 2018). An additional challenge is to define the nature and contribution of the highly numerous additional components in cannabis.

Epilepsy is a condition prone to a “honeymoon” effect, that is, a reduction of initial drug efficacy with prolonged use, often associated with development of tolerance to AEDs (Avanzini, 2006; Dale et al., 2019). It remains unclear if people with epilepsy will develop...
similar tolerance to CBD. At present, there is no published evidence for CBD tolerance in other conditions; however, a recent open-label study reported that around one third of paediatric and adults with different treatment resistance epilepsies showed some tolerance to CBD-enriched oil in terms of reduced control of mean monthly seizure frequency (although concomitant medication was maintained) (Ulél-Sibony, Hausman-Kedem, Fattal-Valevski, & Kramer, 2020). Follow-up studies to further investigate CBD tolerance in epilepsy, and its relevance in comparison to AEDs, are thus warranted.

Epidiolex may be given as a monotherapy in the United States in uncontrolled DS and LGS and Epidiolex as an adjunct to standard anti-epileptic therapies in the European Union. CBD is generally considered a safe drug (Taylor, Gidal, Blakey, Tayo, & Morrison, 2018), in particular, in comparison to standard AEDs (Bergamaschi, Queiroz, Zuardi, & Crippa, 2011; Iffland & Grotenhermen, 2017). Original studies reported that CBD caused some adverse effects, including tiredness, diarrhoea, and changes of appetite/weight (Huestis et al., 2019); however, many such adverse effects occur at doses higher than those used for seizure control. A major CBD effect is inhibition of hepatic drug metabolism leading to recognised, significant increases in the levels of several co-administered AEDs (Gaston, Bebin, Cutter, Liu, & Szafiarski, 2017). A common standard AED used in conjunction with Epidiolex is clobazam. One report (in a preclinical model) has proposed that an interaction between CBD and clobazam may underlie improved anti-epileptic profiles (Anderson et al., 2019), potentially via CBD inhibition of CYP2C19, which metabolises clobazam. However, recent open-label studies have shown that such interactions appear to have no effect on seizure frequency and severity outcomes in the patient population (Gaston et al., 2019; Savage et al., 2019). Isobolographic studies (which are gold standard for pharmacological interactions) for CBD (and 7-OH-CBD) and clobazam (and the major metabolite N-desmethylclobazam) indicated a synergistic action in the MES mouse model of acute generalised seizures that occurred independently of pharmacokinetic interaction (Rana, 2019). A recent meta-analysis further suggests that CBD has anti-seizure efficacy independent of clobazam administration (Lattanzi et al., 2020).

With the recent approval of Epidiolex, several other disease states are the subject of intense investigation with regard to CBD use, with many now progressing to human trials. Recent reviews have outlined clinical work on CBD in, amongst others, Parkinson’s disease and psychosis, society anxiety disorder, Rett syndrome, schizophrenia, cognitive dysfunction, and ulcerative colitis and Crohn’s disease, as well as the potential for CBD to counteract recreational use of cannabis and dependence on opioids (Millar et al., 2019; Pauli, Conroy, Van Den Heuvel, & Park, 2020). In particular, positive results from Phase III trials showing that CBD reduced seizures associated with Tuberosclerosis Complex (TSC) were reported in the GWPCARE6 study (Thiele, Marsh, et al., 2019); this work was also supported by our mechanistic work on CBD effects in a zebrafish model of TSC (Serra et al., 2019). CBD is also being widely investigated in different forms of cancer (Hinz & Ramer, 2019). This activity strongly suggests that CBD therapeutic use will likely soon extend to other conditions.

Thus, preclinical developmental work on CBD at the University of Reading leading to the introduction of Epidiolex for the treatment of severe childhood epilepsies has been recognised by the British Pharmacological Society, which has awarded Stephens, Whalley, and Williams the 2019 Sir James Black Award for Contributions to Drug Discovery. Much of this initial and ongoing work has been published in the British Journal of Pharmacology, including in different themed issues on cannabinoids, and has been presented at European Workshops on Cannabinoid Research organised by the BPS and several annual BPS Pharmacology meetings. The commitment of the BPS to this area of preclinical work has helped push CBD to the clinic for paediatric epilepsies; it is highly likely that additional areas of therapeutic utility will arise in the next few years for CBD and perhaps other plant-derived cannabinoids.

4.1 | Nomenclature of targets and ligands

Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www.guidetopharmacology.org, and are permanently archived in the Concise Guide to PHARMACOLOGY 2019/20 (Alexander et al., 2019).

ACKNOWLEDGEMENTS

This work is a review of the preclinical work for which Gary Stephens, Benjamin Whalley, and Claire Williams were awarded the British Pharmacological Society Sir James Black Award for Contributions to Drug Discovery 2019. The work is submitted as an academic review by Claire Williams and Gary Stephens and is our personal opinion on the work and does not reflect any viewpoint of the major funders of the work, GW Pharmaceuticals, who are also the current employers of the award co-recipient, Benjamin Whalley. We thank and acknowledge GW Pharmaceuticals for their funding of the preclinical work described.

AUTHOR CONTRIBUTIONS

C.W. and G.S. contributed to preclinical work discussed in this review and wrote the manuscript.

CONFLICT OF INTEREST

The authors declare no conflicts of interest.

ORCID

Gary J. Stephens https://orcid.org/0000-0002-8966-4238

REFERENCES

Alexander, S. P., Christopoulos, A., Davenport, A. P., Kelly, E., Mathie, A., Peters, J. A., ... CGTP Collaborators. (2019). The Concise Guide to PHARMACOLOGY 2018/19: G protein-coupled receptors. British Journal of Pharmacology, 176, S21–S141.

Amada, N., Yamasaki, Y., Williams, C. M., & Whalley, B. J. (2013). Cannabidiol (CBDV) suppresses pentylentetrazole (PTZ)-induced
increases in epilepsy-related gene expression. Peer J, 1, e214. https://doi.org/10.7717/peerj.214
Anderson, L. L., Absalom, N. L., Abelev, S. V., Low, I. K., Doohan, P. T., Martin, L. J., ... Arnold, J. C. (2019). Coadministered cannabinoid and clobazam: Preclinical evidence for both pharmacodynamic and pharmacokinetic interactions. Epilepsia, 60, 2224–2234. https://doi.org/10.1111/epi.16355
Avanzini, G. (2006). Is tolerance to antiepileptic drugs clinically relevant? Epilepsia, 47, 1285–1287. https://doi.org/10.1111/j.1528-1167.2006.00616.x
Ben-Shabat, S., Fride, E., Sheskin, T., Tamiri, T., Rhee, M. H., Vogel, Z., ... Mechoulam, R. (1998). An entourage effect: Inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity. European Journal of Pharmacology, 353, 23–31. https://doi.org/10.1016/s0014-2999(98)00392-6
Bergamaschi, M. M., Queiroz, R. H., Zuardi, A. W., & Crippa, J. A. (2011). Safety and side effects of cannabinoid, a Cannabis sativa constituent. Current Drug Safety, 6, 237–249. https://doi.org/10.2174/157488611798280924
Cunha, J. M., Carlini, E. A., Pereira, A. E., Ramos, O. L., Pimentel, C., Gagliardi, R., ... Mechoulam, R. (1980). Chronic administration of cannabinoid to healthy volunteers and epileptic patients. Pharmacology, 21, 175–185. https://doi.org/10.1159/000137430
Dale, T., Downs, J., Olson, H., Bergin, A. M., Smith, S., & Leonard, H. (2019). Cannabis for refractory epilepsy in children: A review focusing on CDKL5 Deficiency Disorder. Epilepsy Research, 151, 31–39. https://doi.org/10.1016/j.ejepes.2019.02.001
Dennis, I., Whalley, B. J., & Stephens, G. J. (2008). Effects of Δ2-tetrahydrocannabivarin on [35S]-GTPγS binding in mouse brain cerebellum and piriform cortex membranes. British Journal of Pharmacology, 154, 1349–1358. https://doi.org/10.1038/bjp.2008.190
Devinsky, O., Cross, J. H., Laux, L., Marsh, E., Miller, I., Nabbout, R., ... Whalley, B. J. (2013). Cannabidiol-rich cannabis extracts are anticonvulsant in mouse and rat via a CB1 receptor-independent mechanism. British Journal of Pharmacology, 170, 679–692. https://doi.org/10.1111/bph.12321
Hinz, B., & Ramer, R. (2019). Anti-tumour actions of cannabinoids. British Journal of Pharmacology, 176, 1384–1394. https://doi.org/10.1111/bjp.14426
Hložek, T., Utš, L., Kadeřábek, L., Baliková, M., Lhotková, E., Horsky, R., ... Páleníček, T. (2017). Pharmacokinetic and behavioural profile of THC, CBD, and THC+CBD combination after pulmonary, oral, and subcutaneous administration in rats and confirmation of conversion in vivo of CBD to THC. European Neuropsychopharmacology, 27, 1223–1237. https://doi.org/10.1016/j.euroence.2017.10.037
Huestis, M. A. (2007). Human cannabinoid pharmacokinetics. Chemistry & Biodiversity, 4, 1770–1804. https://doi.org/10.1002/cbdv.200790152
Huestis, M. A., Solimini, R., Pichini, S., Pacifici, R., Carlier, J., & Busardo, F. P. (2019). Cannabidiol adverse effects and toxicity. Current Neuropharmacology, 17, 974–989. https://doi.org/10.2174/1570159X15666190603179101
Iannotti, F. A., Hill, C. L. Leo, A., Alhusaini, A., Soubrane, C., Mazzarella, E., ... Stephens, G. J. (2014). Nonpsychotropic plant cannabinoids, cannabidiol (CBDV) and cannabinoid (CBD), activate and desensitize transient receptor potential vanilloid 1 (TRPV1) channels in vitro: Potential for the treatment of neuronal hyperexcitability. ACS Chemical Neuroscience, 5, 1131–1141. https://doi.org/10.1021/cn5000524
Ibeas Bib, C., Chen, T., Nunn, A. V., Bazelon, M., Dallas, M., & Whalley, B. J. (2015). Molecular targets of cannabinoid in neurological disorders. Neurotherapeutics, 12, 699–730. https://doi.org/10.1007/s11062-015-0377-3
Ifsand, K., & Grottenherrn, F. (2017). An update on safety and side effects of cannabinoid: A Review of clinical data and relevant animal studies. Cannabis Cannabinoid Res, 2, 139–154. https://doi.org/10.1089/can.2016.0034
Jannnwomened, M., Brodie, M. J., & Kwan, P. (2019). Pharmacoresistance—Epidemiology, mechanisms, and impact on epilepsy treatment. Neuropharmacology, 168, 107790.
Jones, N. A., Glynn, S. E., Akiyama, S., Hill, T. D., Hill, A. J., Weston, S. E., ... Williams, C. M. (2012). Cannabidiol exerts anti-convulsant effects in animal models of temporal lobe and partial seizures. Seizure, 21, 344–352. https://doi.org/10.1016/j.seizure.2012.03.001
Jones, N. A., Hill, A. J., Smith, I., Bevan, S. A., Williams, C. M., Whalley, B. J., & Stephens, G. J. (2010). Cannabidiol displays anti-
patra, p. h., Barker-Haliski, m., white, h. s., whalley, b. j., glynn, s., sandhu, h., ... m. (2018). Cannabidiol improves survival and behavioural comorbidities of Dravet syndrome in mice. British Journal of Pharmacology, 177, 2779–2792. https://doi.org/10.1111/bph.15003

Paudel, K. S., Hammell, D. C., Agu, R. U., Valiveti, S., & Stinchcomb, A. L. (2010). Cannabidiol bioavailability after nasal and transdermal application: Effect of permeation enhancers. Drug Development and Industrial Pharmacy, 36, 1088–1097. https://doi.org/10.1080/036390103657295

Paul, C. S., Conroy, M., Van Den Heuvel, B. D., & Park, S.-H. (2020). Cannabidiol drugs clinical trial outcomes and adverse effects. Frontiers in Pharmacology, 11, 63. https://doi.org/10.3389/fphar.2020.00063

Pez, M. C., Schookraft, K. D., Larson, C., Spring, M. G., & Lopez, H. H. (2017). Assessing the role of serotonin receptors in cannabinoid's anticonvulsant efficacy. Epilepsy & Behavior, 73, 111–118. https://doi.org/10.1016/j.yebeh.2017.04.045

Perry, C. J., Finch, P., Muller-Taubenberger, A., Leung, K.-Y., Warren, E., Oddy, J., ... Stewart, B. (2020). A new mechanism for cannabinoid in regulating the one-carbon cycle and methionine levels in Dicyostelium and in mammalian epilepsy models. British Journal of Pharmacology, 177, 912–928. https://doi.org/10.1111/bph.14892

Pertwee, R. G. (2008). The diverse CB2 and CB1 receptor pharmacology of three plant cannabinooids: Δ9-Tetrahydrocanabidiol, cannabidiol and Δ9-tetrahydrocanabivanin. British Journal of Pharmacology, 153, 199–215. https://doi.org/10.1038/sj.bjp.0707442

Rana, R. R. (2019). Cannabidiol drug-drug interaction with clobazam in an acute mouse model of generalized seizures. Pharmacology 2019 Edinburgh meeting Abstract LB035.

Rosenberg, E., Bazelon, M., Salah, A., Chamberland, S., Nebet, E., Whalley, B. J., ... Tsien, R. (2018). Cannabidiol (CBD) exerts anti-epileptic properties by targeting the LPI-GPR55 lipid signaling system potentiated by seizures. American Epilepsy Society meeting (Abstract 3.052).

Rosenberg, E. C., Tsien, R. W., Whalley, B. J., & Devinsky, O. (2015). Cannabinoids and epilepsy. Neurotherapeutics, 12, 747–786. https://doi.org/10.1007/s13311-015-0375-5

Ryan, D., Drysdale, A. J., Lafourcade, C., Pertwee, R. G., & Platt, B. (2009). Cannabidiol targets mitochondria to regulate intracellular Ca2+ levels. The Journal of Neuroscience, 29, 2053–2063. https://doi.org/10.1523/JNEUROSC.4212-08.2009

Savage, T. E., Sourbourn, J., Bruno, P. L., Skirvin, L. A., Wolper, E. S., Anagnos, C. J., & Thiele, E. A. (2019). Efficacy of cannabidiol in subjects with refractory epilepsy relative to concomitant use of clobazam. Epilepsy Research, 160, 106263.

Senn, L., Cannazza, G., & Blagini, G. (2020). Receptors and channels possibly mediating the effects of phytocannabinoids on seizures and epilepsy. Pharmaceuticals, 13, E174.

Serra, I., Scheldeman, C., Bazelon, M., Whalley, B. J., Dallas, M. L., de Witte, P. A. M., ... Williams, C. M. (2019). Cannabidiol modulates phosphorylated mS6 signaling in a zebrafish model of Tuberous Sclerosis Complex. Behavioural Brain Research, 363, 135–144. https://doi.org/10.1016/j.bbr.2019.01.040

Stephens, G. J. (2009). G-protein-coupled-receptor-mediated presynaptic inhibition in the cerebellum. Trends in Pharmacological Sciences, 30, 421–430. https://doi.org/10.1016/j.tips.2009.05.008

Stephens, G. J., Canti, C., Page, K. M., & Dolphin, A. C. (1998). Role of domain I of neuronal Ca2+ channel α1 subunits in G protein modulation. The Journal of Physiology, 509, 163–169.

Stephens, G. J., & Mochida, S. (2005). G protein α1 subunits mediate presynaptic inhibition of transmitter release from rat superior cervical ganglion neurons in culture. The Journal of Physiology, 563, 765–776. https://doi.org/10.1113/jphysiol.2004.080192

Straiter, A., Dvorakova, M., Zimmovitch, A., & Mackie, K. (2018). Cannabidiol inhibits endocannabinoids signaling in autaptic hippocampal neurons. Molecular Pharmacology, 94, 743–748. https://doi.org/10.1124/mol.118.111864
Sun, Y., & Dolmetsch, R. E. (2018). Investigating the therapeutic mechanism of cannabidiol in a human induced pluripotent stem cell (iPSC)-based model of Dravet syndrome. Cold Spring Harbor Symposia on Quantitative Biology, 83, 185–191. https://doi.org/10.1101/sqb.2018.83.038174

Taylor, L., Gidal, B., Blakey, G., Tayo, B., & Morrison, G. (2018). Phase I, randomized, double-blind, placebo-controlled, single ascending dose, multiple dose, and food effect trial of the safety, tolerability and pharmacokinetics of highly purified cannabidiol in healthy subjects. CNS Drugs, 32, 1053–1067. https://doi.org/10.1007/s40263-018-0578-5

Tham, M., Yilmaz, O., Alaverdashvili, M., Kelly, M. E. M., Denovan-Wright, E. M., & Laprairie, R. B. (2019). Allosteric and orthosteric pharmacology of cannabidiol and cannabidiol-dimethylheptyl at the type 1 and type 2 cannabinoid receptors. British Journal of Pharmacology, 176, 1455–1469. https://doi.org/10.1111/bph.14440

Thiele, E., Marsh, E., Mazurkiewicz-Beldzinska, M., Halford, J. J., Gunning, B., Devinsky, O., ... Roberts, C. (2019). Cannabidiol in patients with Lennox-Gastaut syndrome: Interim analysis of an open-label extension study. Epilepsia, 60, 419–428. https://doi.org/10.1111/epi.14670

Thiele, E. A., Bebin, E. M., Bhatai, H., Jansen, F., Kotulska-Jóźwiak, K., & Lawson, J. A. (2019). Cannabidiol (CBD) treatment in patients with seizures associated with tuberous sclerosis complex: A randomized, double-blind, placebo-controlled phase 3 trial (GWPCARE6). American Epilepsy Society meeting (Abstract 1.293).

Thiele, E. A., Marsh, E. D., French, J. A., Mazurkiewicz-Beldzinska, M., Benbadis, S. R., Joshi, C., ... GWPCARE4 Study Group. (2018). Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): A randomised, double-blind, placebo-controlled phase 3 trial. Lancet, 391, 1085–1096. https://doi.org/10.1016/S0140-6736(18)30136-3

Turner, S. E., Williams, C. M., Iversen, L., & Whalley, B. J. (2017). Molecular pharmacology of phyto-cannabinoids. Progress in the Chemistry of Organic Natural Products, 103, 61–101. https://doi.org/10.1007/978-3-319-45541-9_3

Uliel-Sibony, S., Hausman-Kedem, M., Fattal-Valevski, A., & Kramer, U. (2020). Cannabidiol-enriched oil in children and adults with treatment-resistant epilepsy—Does tolerance exist? Brain and Development. [Epub in print]. S0387–7604(20)30183–2

Wallace, M. J., Wiley, J. L., Martin, B. R., & DeLorenzo, R. J. (2001). Assessment of the role of CB1 receptors in cannabionoid anticonvulsant effects. European Journal of Pharmacology, 428, 51–57. https://doi.org/10.1016/s0014-2999(01)01243-2

Whalley, B. J., Lin, H., Bell, L., Hill, T., Patel, A., Gray, R. A., ... Stephens, G. J. (2018). Species-specific susceptibility to cannabis-induced convulsions. British Journal of Pharmacology, 176, 1506–1523.

Wilkinson, J. D., Whalley, B. J., Baker, D., Pryce, G., Constanti, A., Gibbons, S., ... Williamson, E. M. (2003). Medicinal cannabis: Is Δ9-tetrahydrocannabinol necessary for all its effects? The Journal of Pharmacy and Pharmacology, 55, 1687–1694. https://doi.org/10.1211/002235703022304

Williams, C. M., & Kirkham, T. C. (1999). Anandamide induces overeating: Mediation by central cannabinoid (CB1) receptors. Psychopharmacology, 143, 315–317.

Williams, C. M., Rogers, P. J., & Kirkham, T. C. (1998). Hyperphagia in pre-fed rats following oral Δ9-THC. Physiology & Behavior, 65, 343–346. https://doi.org/10.1016/s0031-9384(98)00170-x

How to cite this article: Williams CM, Stephens GJ. Development of cannabidiol as a treatment for severe childhood epilepsies. Br J Pharmacol. 2020;177:5509–5517. https://doi.org/10.1111/bph.15274